Kailera Therapeutics
NASDAQ · KLRA·Waltham, MA·Mid-cap·Phase 3
Late clinical-stage biotech advancing a diversified pipeline of GLP-1-based therapies for obesity. Lead candidate ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist licensed from Hengrui, is in global Phase 3. Founded in 2024, Kailera raised a $400M Series A and $600M Series B before a ~$625M Nasdaq IPO in April 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Corporate Presentation - May 2026 | Corporate overview | May 1, 2026 | 40 |